Belgian clinical stage biotech company Remynd has extended its series-B round to €24m, with backing from Korys Investments, FPIM, KU Leuven, PMV and BNP Paribas Fortis Private Equity.
Belgian clinical stage biotech company Remynd has extended its series-B round to €24m, with backing from Korys Investments, FPIM, KU Leuven, PMV and BNP Paribas Fortis Private Equity.